A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells | Citedby Results | Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Mol Cancer Ther (2018) 17 (12): 2622–2632.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Palladium–Protein Oxidative Addition Complexes by Amine-Selective Acylation

Heemal H. Dhanjee
Ivan Buslov
Ian W. Windsor
Ronald T. Raines
Bradley L. Pentelute
Stephen L. Buchwald

Journal of the American Chemical Society (2020) 142 (51): 21237.

Modifying Adaptive Therapy to Enhance Competitive Suppression

Elsa Hansen
Andrew F. Read

Cancers (2020) 12 (12): 3556.

Chameleonic Behavior of the α‐Methylcyclopropyl Group and Its Through‐Space Interactions: A Route to Stabilized Three Redox States in Diarylnitroxides

Oleg A. Levitskiy
Dmitry A. Dulov
Alexey V. Bogdanov
Yury K. Grishin
Sergey E. Nefedov
Tatiana V. Magdesieva

Chemistry – A European Journal (2020) 26 (30): 6793.

Phenotype of ribonuclease 1 deficiency in mice

Emily R. Garnett
Jo E. Lomax
Bassem M. Mohammed
David Gailani
John P. Sheehan
Ronald T. Raines

RNA (2019) 25 (8): 921.

Esterification Delivers a Functional Enzyme into a Human Cell

Valerie T. Ressler
Kalie A. Mix
Ronald T. Raines

ACS Chemical Biology (2019) 14 (4): 599.

Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases

Nadezhda Mironova
Valentin Vlassov

Frontiers in Pharmacology (2019) 10